Genzyme/TKT Fabry Agents Receive Co-Exclusive Orphan Drug Status In EU

Genzyme's Fabrazyme and Transkaryotic Therapies' Replagal will split the 5,000-patient Fabry's disease market in Europe following the awarding of co-exclusive orphan status by the European Commission.